(Hong Kong, Shanghai, 30 March 2025) Fosun International Limited (HKEX stock code: 00656, “Fosun International”), together with its subsidiaries (“Fosun” or the “Group”), today announced its annual results for the year ended 31 December 2024 (the “Reporting Period”).

Fosun International (HKEX stock code: 00656, hereinafter referred to as "Fosun International", "Fosun", or the "Company") has successfully completed the refinancing of a USD 870 million equivalent syndicated loan due on March 28, 2025. Of this amount, USD 675 million equivalent was secured through a newly arranged syndicated loan. Consistent with the Company’s past practices, the new syndicated loan includes a greenshoe option, allowing additional banks to participate.

(March 25, 2025, Shanghai, China) On March 25, 2025, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”or “the Group”; Stock Code: 600196.SH, 02196.HK),a leading global pharmaceutical and healthcare company driven by innovation, announced its annual results for the year ended 31 December 2024 (“the Reporting Period”).

Shanghai, China, March 24, 2025 – Henlius (2696.HK) announced its 2024 annual results. During the reporting period, Henlius’ total revenue reached approximately RMB5.7244 billion, representing an increase of 6.1% YoY. The net profit reached RMB820.5 million, a 50.3% YoY growth, with a net profit margin of 14.3%, up by 41.6% YoY. This marks Henlius' second consecutive year of full-year profitability following its first profitable year in 2023. The increasing commercial sales of core products have been a key driver of profitability, with total product sales revenue reaching approximately RMB4.9335 billion, an increase of 8.3% YoY. Additionally, the company’s annual R&D expenditure reached RMB1.8405 billion, representing an increase of 28.4% YoY.

Hong Kong, March 19, 2025 -- Sisram Medical Ltd (the “Company” or “Sisram”, 1696.HK; together with its subsidiaries collectively referred to as the “Group”), a global consumer wellness group, featuring a distinguished synergistic ecosystem of business building blocks and consumer-focused approaches including Energy-Based Devices (EBD), Injectables, alongside other complementary offerings, announced its audited consolidated annual results for the year ended December 31, 2024 (the “Reporting Period”).

Shanghai, China, March 19, 2025 - Shanghai Henlius Biotech, Inc. (2696.HK) announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for HLX22, the company's innovative anti-HER2 monoclonal antibody (mAb) for the treatment of gastric cancer.

March 13, 2025 – Fosun Pharma announced that its subsidiary S-INFINITY Co., Ltd. (“S-INFINITY”) recently received approval from the National Medical Products Administration (NMPA) to conduct clinical trials for XH-S003 Capsule (registration category: chemical drug Class 1; hereinafter referred to as “XH-S003”) for the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH). S-INFINITY plans to initiate Phase 2 clinical trials in Mainland China (excluding Hong Kong, Macao, and Taiwan regions) once conditions are met.

March 10, 2025 – Recently, Fosun Pharma announced that the marketing authorization application for its independently developed new drug, foritinib Succinate Capsules (project code: SAF-189, foritinib, hereinafter referred to as "New Drug"), has been accepted by the National Medical Products Administration (NMPA). The New Drug is primarily indicated for the treatment of non-small cell lung cancer (ALK+) and non-small cell lung cancer (ROS1+), etc. The indication under this application is for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC).

Recently, Henlius successfully hosted an in-person clinical investigator meeting for the HLX22-GC-301 study in Tokyo, Japan. The meeting focused on the international phase 3 clinical trial (HLX22-GC-301) of HLX22, our innovative anti-HER2 monoclonal antibody (mAb)